Management of Hepatitis C Infection
Summary
- High SVR12 rates observed with 12 weeks of sofosbuvir/velpatasvir/voxilaprevir in phase III trials involving DAA-experienced patients
- POLARIS-1: SVR12 96% in genotype 1-6 HCV infection[Bourlière 2017]
- POLARIS-4: SVR12 98% vs 90% with 12 weeks of sofosbuvir/velpatasvir in genotype 1-4 vs 1-3 HCV infection, respectively[Bourlière 2017]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment